A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR741 in Healthy Volunteers

Trial Profile

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR741 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs SPR 741 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; First in man
  • Sponsors Spero Therapeutics
  • Most Recent Events

    • 04 Oct 2017 Status changed from recruiting to completed.
    • 03 Oct 2017 Results published in the Spero Therapeutics Media Release
    • 12 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top